Related references
Note: Only part of the references are listed.Estimation of the Prevalence of Progressive Fibrosing Interstitial Lung Diseases: Systematic Literature Review and Data from a Physician Survey
Amy Olson et al.
ADVANCES IN THERAPY (2021)
Interstitial lung disease in a veterans affairs regional network; a retrospective cohort study
Armando Bedoya et al.
PLOS ONE (2021)
Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial
Toby M. Maher et al.
LANCET RESPIRATORY MEDICINE (2020)
Cost-effectiveness of ambulatory oxygen in improving quality of life in fibrotic lung disease: preliminary evidence from the AmbOx Trial
Jennifer A. Whitty et al.
EUROPEAN RESPIRATORY JOURNAL (2020)
The clinical and economic burden of systemic sclerosis related interstitial lung disease
Kathleen Morrisroe et al.
RHEUMATOLOGY (2020)
Hospital-Based Resource Use and Costs Among Patients With Idiopathic Pulmonary Fibrosis Enrolled in the Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry
Yanni Fan et al.
CHEST (2020)
Healthcare Resource Utilization Among Patients in England with Systemic Sclerosis-Associated Interstitial Lung Disease: A Retrospective Database Analysis
Alicia Gayle et al.
ADVANCES IN THERAPY (2020)
Treatment patterns, healthcare resource utilization, and costs among patients with idiopathic pulmonary fibrosis treated with antifibrotic medications in US-based commercial and Medicare Supplemental claims databases: a retrospective cohort study
Mitra Corral et al.
BMC PULMONARY MEDICINE (2020)
Costs of Workplace Productivity Loss in Patients with Connective Tissue Disease-associated Interstitial Lung Disease
Mohmmed Algamdi et al.
ANNALS OF THE AMERICAN THORACIC SOCIETY (2020)
Health Care Costs at the End of Life for Patients with Idiopathic Pulmonary Fibrosis Evaluation of a Pilot Multidisciplinary Collaborative Interstitial Lung Disease Clinic
Meena Kalluri et al.
ANNALS OF THE AMERICAN THORACIC SOCIETY (2020)
Cost-Effectiveness Analysis of Nintedanib Versus Pirfenidone in Idiopathic Pulmonary Fibrosis in Belgium
C. Rinciog et al.
PHARMACOECONOMICS-OPEN (2020)
Economic Burden of Illness Among Commercially Insured Patients with Systemic Sclerosis with Interstitial Lung Disease in the USA: A Claims Data Analysis
Zhou Zhou et al.
ADVANCES IN THERAPY (2019)
Costs of Workplace Productivity Loss in Patients With Fibrotic Interstitial Lung Disease
Mohmmed Algamdi et al.
CHEST (2019)
King's Brief Interstitial Lung Disease questionnaire: responsiveness and minimum clinically important difference
Claire M. Nolan et al.
EUROPEAN RESPIRATORY JOURNAL (2019)
Economic burden of incident interstitial lung disease (ILD) and the impact of comorbidity on costs of care
Anna Lena Frank et al.
RESPIRATORY MEDICINE (2019)
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases
K. R. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Rheumatoid Arthritis-Interstitial Lung Disease in the United States: Prevalence, Incidence, and Healthcare Costs and Mortality
Karina Raimundo et al.
JOURNAL OF RHEUMATOLOGY (2019)
Characterizing idiopathic pulmonary fibrosis patients using US Medicare-advantage health plan claims data
Kathleen Mortimer et al.
BMC PULMONARY MEDICINE (2019)
All-cause Healthcare Costs and Mortality in Patients with Systemic Sclerosis with Lung Involvement
Aryeh Fischer et al.
JOURNAL OF RHEUMATOLOGY (2018)
Health economic evaluation in idiopathic pulmonary fibrosis in France
Fanny Porte et al.
CURRENT MEDICAL RESEARCH AND OPINION (2018)
Economic consequences of idiopathic pulmonary fibrosis in Denmark
Ole Hilberg et al.
ERJ OPEN RESEARCH (2018)
Clinical and economic burden of idiopathic pulmonary fibrosis in Quebec, Canada
Jean-Eric Tarride et al.
CLINICOECONOMICS AND OUTCOMES RESEARCH (2018)
The Economic Burden of Asthma in the United States, 2008-2013
Tursynbek Nurmagambetov et al.
ANNALS OF THE AMERICAN THORACIC SOCIETY (2018)
Understanding and improving the one and three times GDP per capita cost-effectiveness thresholds
Lisa A. Robinson et al.
HEALTH POLICY AND PLANNING (2017)
A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK
C. Rinciog et al.
PHARMACOECONOMICS (2017)
Health care burden and medical resource utilisation of idiopathic pulmonary fibrosis in Korea
S. W. Kim et al.
INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE (2017)
The Estimation and Inclusion of Presenteeism Costs in Applied Economic Evaluation: A Systematic Review
Jesse Kigozi et al.
VALUE IN HEALTH (2017)
Retrospective observational study of trends in hospital admissions for idiopathic pulmonary fibrosis in Spain (2004-2013) using administrative data
Fernando Pedraza-Serrano et al.
BMJ OPEN (2017)
What Is the Purpose of the Orphan Drug Act?
Matthew Herder
PLOS MEDICINE (2017)
Hospital cost and length of stay in idiopathic pulmonary fibrosis
Joshua J. Mooney et al.
JOURNAL OF MEDICAL ECONOMICS (2017)
Burden of Idiopathic Pulmonary Fibrosis Progression: A 5-Year Longitudinal Follow-Up Study
Vincent Cottin et al.
PLOS ONE (2017)
Clinical and economic burden of idiopathic pulmonary fibrosis: a retrospective cohort study
Karina Raimundo et al.
BMC PULMONARY MEDICINE (2016)
Cryobiopsy in the Diagnosis of Diffuse Interstitial Lung Disease: Yield and Cost-Effectiveness Analysis
Fernanda Hernandez-Gonzalez et al.
ARCHIVOS DE BRONCONEUMOLOGIA (2015)
The clinical effectiveness and cost-effectiveness of treatments for idiopathic pulmonary fibrosis: a systematic review and economic evaluation
[Anonymous]
HEALTH TECHNOLOGY ASSESSMENT (2015)
Cryobiopsy in the Diagnosis of Diffuse Interstitial Lung Disease: Yield and Cost-Effectiveness Analysis
Fernanda Hernandez-Gonzalez et al.
ARCHIVOS DE BRONCONEUMOLOGIA (2015)
Health Care Utilization and Costs of Idiopathic Pulmonary Fibrosis in US Medicare Beneficiaries Aged 65 Years and Older
Harold R. Collard et al.
ANNALS OF THE AMERICAN THORACIC SOCIETY (2015)
Updating Cost-Effectiveness - The Curious Resilience of the $50,000-per-QALY Threshold
Peter J. Neumann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias
William D. Travis et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2013)
The Increasing Secondary Care Burden of Idiopathic Pulmonary Fibrosis Hospital Admission Trends in England From 1998 to 2010
Vidya Navaratnam et al.
CHEST (2013)
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement
Don Husereau et al.
EUROPEAN JOURNAL OF HEALTH ECONOMICS (2013)
Idiopathic Pulmonary Fibrosis: Diagnosis and Epidemiology
Amy L. Olson et al.
CLINICS IN CHEST MEDICINE (2012)
Burden of illness in idiopathic pulmonary fibrosis
Harold R. Collard et al.
JOURNAL OF MEDICAL ECONOMICS (2012)
A clinician's guide to correct cost-effectiveness analysis: Think incremental not average
Jeffrey S. Hoch et al.
CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE (2008)
The NICE cost-effectiveness threshold - What it is and what that means
Christopher McCabe et al.
PHARMACOECONOMICS (2008)
Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold
Scott D Grosse
Expert Review of Pharmacoeconomics & Outcomes Research (2008)
Cost-effectiveness of lung transplantation in relation to type of end-stage pulmonary disease
H Groen et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2004)
Share Paper
